Tenaya Therapeutics’ (TNYA) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their sell (d-) rating on shares of Tenaya Therapeutics (NASDAQ:TNYA) in a research note released on Friday morning,Weiss Ratings reports.

Several other equities research analysts have also commented on the company. Chardan Capital reissued a “buy” rating and set a $9.00 price target on shares of Tenaya Therapeutics in a research note on Thursday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Tenaya Therapeutics in a research note on Tuesday, September 2nd. Finally, Wall Street Zen raised Tenaya Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.25.

Tenaya Therapeutics Price Performance

Shares of NASDAQ:TNYA opened at $1.66 on Friday. The business’s 50 day simple moving average is $1.47 and its 200-day simple moving average is $0.90. The firm has a market capitalization of $270.54 million, a price-to-earnings ratio of -1.73 and a beta of 3.15. Tenaya Therapeutics has a 12 month low of $0.36 and a 12 month high of $4.01.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.06. On average, equities analysts anticipate that Tenaya Therapeutics will post -1.35 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Nuveen LLC acquired a new position in Tenaya Therapeutics in the 1st quarter valued at $129,000. Wealth Enhancement Advisory Services LLC acquired a new position in Tenaya Therapeutics in the 1st quarter valued at $33,000. Ieq Capital LLC acquired a new position in Tenaya Therapeutics in the 1st quarter valued at $95,000. DAFNA Capital Management LLC acquired a new position in Tenaya Therapeutics in the 1st quarter valued at $27,000. Finally, CWM LLC raised its holdings in Tenaya Therapeutics by 14,231.7% in the 1st quarter. CWM LLC now owns 71,945 shares of the company’s stock valued at $41,000 after acquiring an additional 71,443 shares during the last quarter. 90.54% of the stock is currently owned by institutional investors and hedge funds.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.